ZOETIS INC. (ZTS) Valuation

Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry...

ZOETIS INC. (ZTS) currently trades at a P/E ratio of 12.12 (historical range: 11.48–38.34, median: 25.45), placing it at the 6th percentile — cheap relative to its history, P/S ratio of 3.37 (range: 3.19–10.08, 6th percentile — cheap relative to its history), EV/EBITDA of 51.64 (range: 16.98–98.52, 68th percentile).

Over the historical period (2024-08-30 to 2026-08-28), ZOETIS INC.'s P/E ratio has contracted by 40% over the observed period (from an average of 30.7 to 18.5).

ZOETIS INC. appears undervalued relative to its historical range, with most valuation metrics below their median levels.

Historical Valuation Metrics

MetricCurrentMinMedianMaxPercentileAssessment
P/E Ratio12.1211.4825.4538.346thcheap relative to its history
P/S Ratio3.373.197.0710.086thcheap relative to its history
EV/EBITDA51.6416.9839.1898.5268thabove its historical average
FCF Yield0.010.010.010.0527thabove its historical average
Current Price: $77.25
Market Cap: $31.9B
Sector: Healthcare